0.53
price up icon7.72%   0.038
after-market Dopo l'orario di chiusura: .54 0.01 +1.89%
loading
Precedente Chiudi:
$0.492
Aprire:
$0.49
Volume 24 ore:
6.28M
Relative Volume:
0.95
Capitalizzazione di mercato:
$114.11M
Reddito:
$52.29M
Utile/perdita netta:
$-134.84M
Rapporto P/E:
-0.7067
EPS:
-0.75
Flusso di cassa netto:
$-117.11M
1 W Prestazione:
+13.98%
1M Prestazione:
-13.40%
6M Prestazione:
-73.63%
1 anno Prestazione:
-10.43%
Intervallo 1D:
Value
$0.49
$0.5583
Intervallo di 1 settimana:
Value
$0.4501
$0.5583
Portata 52W:
Value
$0.304
$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name
Nome
Sangamo Therapeutics Inc
Name
Telefono
(510) 970-6000
Name
Indirizzo
501 CANAL BLVD., RICHMOND, CA
Name
Dipendente
183
Name
Cinguettio
@sangamotx
Name
Prossima data di guadagno
2025-05-02
Name
Ultimi documenti SEC
Name
SGMO's Discussions on Twitter

Confronta SGMO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SGMO
Sangamo Therapeutics Inc
0.53 114.11M 52.29M -134.84M -117.11M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-13 Aggiornamento Truist Hold → Buy
2024-12-10 Reiterato H.C. Wainwright Buy
2023-11-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2023-04-28 Downgrade BofA Securities Neutral → Underperform
2023-02-27 Aggiornamento Wedbush Neutral → Outperform
2023-01-06 Downgrade BofA Securities Buy → Neutral
2022-06-13 Ripresa Wedbush Neutral
2021-05-04 Iniziato RBC Capital Mkts Outperform
2021-01-07 Ripresa Guggenheim Neutral
2021-01-06 Iniziato Stifel Hold
2020-12-16 Ripresa H.C. Wainwright Buy
2020-09-08 Iniziato BofA Securities Buy
2020-07-07 Iniziato SunTrust Buy
2019-08-26 Iniziato H.C. Wainwright Buy
2018-11-14 Downgrade JP Morgan Overweight → Neutral
2018-11-09 Downgrade Guggenheim Buy → Neutral
2018-10-10 Iniziato Guggenheim Buy
2018-06-20 Iniziato BofA/Merrill Buy
2017-11-15 Aggiornamento Piper Jaffray Neutral → Overweight
2017-06-22 Ripresa Jefferies Buy
2016-11-01 Downgrade Wedbush Outperform → Neutral
2016-10-19 Downgrade Piper Jaffray Overweight → Neutral
2015-12-04 Iniziato Wells Fargo Outperform
2015-10-23 Ripresa Jefferies Buy
2013-05-03 Iniziato BioLogic Equity Research Sell
2011-02-23 Reiterato JMP Securities Mkt Outperform
2010-07-29 Reiterato Wedbush Outperform
2009-10-19 Iniziato Brean Murray Sell
2009-10-07 Reiterato Leerink Swann Outperform
2009-08-25 Reiterato JMP Securities Mkt Outperform
Mostra tutto

Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie

pulisher
Jun 03, 2025

H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO) - MSN

Jun 03, 2025
pulisher
Jun 01, 2025

5 Best Stem Cell Companies to Invest In (June 2025) - Securities.io

Jun 01, 2025
pulisher
May 30, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

May 30, 2025
pulisher
May 29, 2025

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - Zenopa

May 29, 2025
pulisher
May 27, 2025

Sangamo Therapeutics’ SWOT analysis: genomic medicine firm faces cash crunch - Investing.com

May 27, 2025
pulisher
May 26, 2025

Lazard Asset Management LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World

May 26, 2025
pulisher
May 24, 2025

Captrust Financial Advisors Makes New $30,000 Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World

May 24, 2025
pulisher
May 22, 2025

StockNews.com Initiates Coverage on Sangamo Therapeutics (NASDAQ:SGMO) - Defense World

May 22, 2025
pulisher
May 16, 2025

Barclays Issues Pessimistic Forecast for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price - Defense World

May 16, 2025
pulisher
May 15, 2025

Sangamo Biosciences’ Earnings Call: Progress Amid Challenges - TipRanks

May 15, 2025
pulisher
May 14, 2025

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - MSN

May 14, 2025
pulisher
May 14, 2025

Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | SGMO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Sangamo (SGMO) Price Target Reduced by Barclays | SGMO Stock New - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Sangamo Biosciences Announces $23 Million Share Offering - TipRanks

May 14, 2025
pulisher
May 14, 2025

Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Sangamo Therapeutics (SGMO) Projects 2025 Operating Expenses Ami - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics prices $23M securities offering - MSN

May 13, 2025
pulisher
May 13, 2025

Market Setbacks: Major Stocks Face Financial Hurdles - Finimize

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics (SGMO) Announces $23M Capital Raise - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics (SGMO) Reports First Quarter Revenue Below - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics (SGMO) Q1 Earnings Miss Expectations - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day - BioSpace

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 13, 2025
pulisher
May 12, 2025

Sangamo Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 12, 2025
pulisher
May 12, 2025

Transcript : Sangamo Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Earnings call transcript: Sangamo Therapeutics faces stock drop after Q1 2025 call - Investing.com Nigeria

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Firs - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics (SGMO) Reports First Quarter Revenue Below Expectations | SGMO Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwri - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SGMO) - Seeking Alpha

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results | SGMO Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results - BioSpace

May 12, 2025
pulisher
May 12, 2025

Sangamo: Q1 Earnings Snapshot - San Antonio Express-News

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Zenopa

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics (SGMO) Anticipates Q1 Earnings Release - GuruFocus

May 12, 2025
pulisher
May 08, 2025

Sangamo hits milestone toward accelerated approval for ST-920 - Fabry Disease News

May 08, 2025
pulisher
May 07, 2025

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease - BioSpace

May 07, 2025
pulisher
May 06, 2025

Sangamo Biosciences Receives Nasdaq Deficiency Notice - TipRanks

May 06, 2025

Sangamo Therapeutics Inc Azioni (SGMO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
Capitalizzazione:     |  Volume (24 ore):